Genes & Nutrition

, Volume 7, Issue 1, pp 63–74

Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment

Research Paper

Abstract

Systemic chemotherapy is the only current method of treatment that provides some chance for long-term survival in patients with advanced or metastatic cancer. γ-Tocotrienol is a natural form of vitamin E found in high concentrations in palm oil and displays potent anticancer effects, but limited absorption and transport of by the body has made it difficult to obtain and sustain therapeutic levels in the blood and target tissues. Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase and are an example of a promising cancer chemotherapeutic agent whose clinical usefulness has been limited due to high-dose toxicity. Similarly, erlotinib and gefitinib are anticancer agents that inhibit the activation of individual HER/ErbB receptor subtypes, but have shown limited clinical success because of heterodimerization between different EGF receptor family members that can rescue cancer cells from agents directed against a single receptor subtype. Recent studies have investigated the anticancer effectiveness of low-dose treatment of various statins or EGF receptor inhibitors alone and in combination with γ-tocotrienol on highly malignant +SA mouse mammary epithelial cells in vitro. Combined treatment with subeffective doses of γ-tocotrienol with these other chemotherapeutic agents resulted in a synergistic inhibition of +SA cell growth and viability. These findings strongly suggest that combined treatment of γ-tocotrienol with other anticancer agents may not only provide an enhanced therapeutic response but also provide a means to avoid the toxicity, low bioavailability, or limited therapeutic action associated with high-dose monotherapy.

Keywords

γ-Tocotrienol Statins Erlotinib Gefitinib Breast cancer Vitamin E 

References

  1. American Cancer Society (2009) Cancer facts and figures. American Cancer Society Inc., Atlanta, GAGoogle Scholar
  2. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57:1569–1574PubMedGoogle Scholar
  3. Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23:4215–4224PubMedCrossRefGoogle Scholar
  4. Bachawal SV, Wali VB, Sylvester PW (2010a) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 30:429–437PubMedGoogle Scholar
  5. Bachawal SV, Wali VB, Sylvester PW (2010b) Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10:84PubMedCrossRefGoogle Scholar
  6. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J (1994) Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353–361PubMedCrossRefGoogle Scholar
  7. Baserga R, Wiebel F (1969) The cell cycle of mammalian cells. Int Rev Exp Pathol 7:1–30PubMedGoogle Scholar
  8. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19:2474–2488PubMedCrossRefGoogle Scholar
  9. Britten CD (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3:1335–1342PubMedGoogle Scholar
  10. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121–1128PubMedGoogle Scholar
  11. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA (2006) Cell cycle control in breast cancer cells. J Cell Biochem 97:261–274PubMedCrossRefGoogle Scholar
  12. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707–8714PubMedCrossRefGoogle Scholar
  13. Carraway KL 3rd, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5–8PubMedCrossRefGoogle Scholar
  14. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19PubMedGoogle Scholar
  15. Coleman ML, Marshall CJ, Olson MF (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5:355–366PubMedCrossRefGoogle Scholar
  16. Cottrell RC (1991) Introduction: nutritional aspects of palm oil. Am J Clin Nutr 53:989S–1009SPubMedGoogle Scholar
  17. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262–267PubMedCrossRefGoogle Scholar
  18. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499–2513PubMedCrossRefGoogle Scholar
  19. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL (1989) Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87:28S–38SPubMedCrossRefGoogle Scholar
  20. Goh SH, Hew NF, Norhanom AW, Yadav M (1994) Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 57:529–531PubMedCrossRefGoogle Scholar
  21. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425–430PubMedCrossRefGoogle Scholar
  22. Goldstein JL, DeBose-Boyd RA, Brown MS (2006) Protein sensors for membrane sterols. Cell 124:35–46PubMedCrossRefGoogle Scholar
  23. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609–641PubMedCrossRefGoogle Scholar
  24. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95:185–194PubMedCrossRefGoogle Scholar
  25. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67–108PubMedCrossRefGoogle Scholar
  26. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Muller GA, Mossner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG (2008) Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer 98:1525–1532PubMedCrossRefGoogle Scholar
  27. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254–264PubMedGoogle Scholar
  28. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI (1998) c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949–1957PubMedCrossRefGoogle Scholar
  29. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW (1989) Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248:498–505PubMedGoogle Scholar
  30. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339–345PubMedCrossRefGoogle Scholar
  31. Ling YH, Lin R, Perez-Soler R (2008) Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 74:793–806PubMedCrossRefGoogle Scholar
  32. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 76:1748–1754PubMedCrossRefGoogle Scholar
  33. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11:2398–2407PubMedCrossRefGoogle Scholar
  34. Marshall E (1993) Epidemiology. Search for a killer: focus shifts from fat to hormones [news] [see comments]. Science 259:618–621PubMedCrossRefGoogle Scholar
  35. Massague J (2004) G1 cell-cycle control and cancer. Nature 432:298–306PubMedCrossRefGoogle Scholar
  36. Massague J, Pandiella A (1993) Membrane-anchored growth factors. Annu Rev Biochem 62:515–541PubMedCrossRefGoogle Scholar
  37. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066–2076PubMedGoogle Scholar
  38. McIntyre BS, Briski KP, Gapor A, Sylvester PW (2000a) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224:292–301PubMedCrossRefGoogle Scholar
  39. McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW (2000b) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35:171–180PubMedCrossRefGoogle Scholar
  40. Medina D (1974) Mammary tumorigenesis in chemical carcinogen-treated mice. II. Dependence on hormone stimulation for tumorigenesis. J Natl Cancer Inst 53:223–226PubMedGoogle Scholar
  41. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229:567–585Google Scholar
  42. Nagasawa H, Yanai R, Taniguchi H (1976) Importance of mammary gland DNA synthesis on carcinogen-induced mammary tumorigenesis in rats. Cancer Res 36:2223–2226PubMedGoogle Scholar
  43. Nakanishi M, Goldstein JL, Brown MS (1988) Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263:8929–8937PubMedGoogle Scholar
  44. Nakayama M, Ju HR, Sugano M, Hirose N, Ueki T, Doi F, Eynard AR (1993) Effect of dietary fat and cholesterol on dimethylbenz[a]-anthracene-induced mammary tumorigenesis in Sprague-Dawley rats. Anticancer Res 13:691–698PubMedGoogle Scholar
  45. Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650–3657PubMedCrossRefGoogle Scholar
  46. Norbury C, Nurse P (1992) Animal cell cycles and their control. Annu Rev Biochem 61:441–470PubMedCrossRefGoogle Scholar
  47. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65–72PubMedCrossRefGoogle Scholar
  48. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10:1–21PubMedCrossRefGoogle Scholar
  49. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H (2004) Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br J Cancer 90:236–244PubMedCrossRefGoogle Scholar
  50. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999) ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274:17209–17218PubMedCrossRefGoogle Scholar
  51. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167PubMedCrossRefGoogle Scholar
  52. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ (1993) Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268:11230–11238PubMedGoogle Scholar
  53. Rogers AE, Lee SY (1986) Chemically-induced mammary gland tumors in rats: modulation by dietary fat. Prog Clin Biol Res 222:255–282PubMedGoogle Scholar
  54. Russo IH, Russo J (1978) Developmental stage of the rat mammary gland as determinant of its susceptibility to 7, 12-dimethylbenz[a]anthracene. J Natl Cancer Inst 61:1439–1449PubMedGoogle Scholar
  55. Samant GV, Sylvester PW (2006) gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 39:563–574PubMedCrossRefGoogle Scholar
  56. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225PubMedCrossRefGoogle Scholar
  57. Sears RC, Nevins JR (2002) Signaling networks that link cell proliferation and cell fate. J Biol Chem 277:11617–11620PubMedCrossRefGoogle Scholar
  58. Seeger H, Wallwiener D, Mueck AO (2003) Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111:47–48PubMedCrossRefGoogle Scholar
  59. Shah SJ, Sylvester PW (2005) Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med 230:235–241Google Scholar
  60. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783PubMedCrossRefGoogle Scholar
  61. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059–1065PubMedCrossRefGoogle Scholar
  62. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE (2003) Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24:453–459PubMedCrossRefGoogle Scholar
  63. Shibata MA, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25:1887–1898PubMedCrossRefGoogle Scholar
  64. Shirode AB, Sylvester PW (2010) Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 64:327–332Google Scholar
  65. Sundram K, Khor HT, Ong AS (1990) Effect of dietary palm oil and its fractions on rat plasma and high density lipoprotein lipids. Lipids 25:187–193PubMedCrossRefGoogle Scholar
  66. Sylvester PW, Shah SJ (2005) Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 10:699–709PubMedCrossRefGoogle Scholar
  67. Sylvester PW, Theriault A (2003) Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res 1:121–136Google Scholar
  68. Sylvester PW, Aylsworth CF, Van Vugt DA, Meites J (1983) Effects of alterations in early hormonal environment on development and hormone dependency of carcinogen-induced mammary tumors in rats. Cancer Res 43:5342–5346PubMedGoogle Scholar
  69. Sylvester PW, Ip C, Ip MM (1986a) Effects of high dietary fat on the growth and development of ovarian-independent carcinogen-induced mammary tumors in rats. Cancer Res 46:763–769PubMedGoogle Scholar
  70. Sylvester PW, Russell M, Ip MM, Ip C (1986b) Comparative effects of different animal and vegetable fats fed before and during carcinogen administration on mammary tumorigenesis, sexual maturation, and endocrine function in rats. Cancer Res 46:757–762PubMedGoogle Scholar
  71. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483–491PubMedGoogle Scholar
  72. Toker A (2000) Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol 57:652–658PubMedGoogle Scholar
  73. Torii S, Yamamoto T, Tsuchiya Y, Nishida E (2006) ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 97:697–702PubMedCrossRefGoogle Scholar
  74. Tran H, Brunet A, Griffith EC, Greenberg ME (2003) The many forks in FOXO’s road. Sci STKE 2003:RE5PubMedCrossRefGoogle Scholar
  75. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y (1997) Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16:4938–4950PubMedCrossRefGoogle Scholar
  76. Vogel VG (1993) Breast cancer risk: weaving facts into fabric. Breast Cancer Res Treat 28:91–96PubMedCrossRefGoogle Scholar
  77. Wali VB, Sylvester PW (2007) Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 42:1113–1123PubMedCrossRefGoogle Scholar
  78. Wali VB, Bachawal SV, Sylvester PW (2009a) Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids 44:925–934PubMedCrossRefGoogle Scholar
  79. Wali VB, Bachawal SV, Sylvester PW (2009b) Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood) 234:639–650CrossRefGoogle Scholar
  80. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.College of PharmacyUniversity of Louisiana at MonroeMonroeUSA

Personalised recommendations